
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000Prime Rep</journal-id><journal-id journal-id-type="iso-abbrev">F1000Prime Rep</journal-id><journal-title-group><journal-title>F1000Prime Reports</journal-title></journal-title-group><issn pub-type="epub">2051-7599</issn><publisher><publisher-name>Faculty of 1000 Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4126534</article-id><article-id pub-id-type="doi">10.12703/P6-69</article-id><article-id pub-id-type="publisher-id">69</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Renzoni</surname><given-names>Elisabetta</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><email xlink:href="mailto:e.renzoni@imperial.ac.uk">e.renzoni@imperial.ac.uk</email><ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty/member/1998511657250735"/></contrib><contrib contrib-type="author"><name><surname>Srihari</surname><given-names>Veeraraghavan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sestini</surname><given-names>Piersante</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label><institution>Interstitial Lung Disease Unit, Royal Brompton Hospital and National Heart and Lung Institute</institution><addr-line>Imperial College London, Emmanuel Kaye Building, 1B Manresa Road, London SW3 6LR</addr-line><country>UK</country></aff><aff id="aff2"><label>2</label><institution>Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Emory University</institution><addr-line>1365 Clifton Rd NE Rm A 4319, Atlanta, GA 30322</addr-line><country>USA</country></aff><aff id="aff3"><label>3</label><institution>Respiratory Medicine Department, Ospedale “Le Scotte”, University of Siena, viale Bracci</institution><addr-line>53100 Siena</addr-line><country>Italy</country></aff></contrib-group><pub-date pub-type="epub"><day>01</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>6</volume><elocation-id>69</elocation-id><permissions><copyright-statement>© 2014 Faculty of 1000 Ltd</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/legalcode"><license-p>All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Idiopathic pulmonary fibrosis (IPF) is likely to result from the interaction between environmental exposures, including cigarette smoke, and genetic predisposition. </plain></SENT>
<SENT sid="2" pm="."><plain>This review focuses on clues provided by recent genetic association studies and other selected data and hypotheses. </plain></SENT>
<SENT sid="3" pm="."><plain>In IPF, association with surfactant mutations has highlighted the importance of type II epithelial cells, while shortened telomeres in some patients suggest that accelerated aging may play a role in the pathogenesis of lung fibrosis, possibly by affecting the renewal/differentiation potential of epithelial cells. </plain></SENT>
<SENT sid="4" pm="."><plain>The finding that a common variant in mucin 5B predisposes individuals to both familial and sporadic IPF suggests a hitherto under-investigated role of bronchiolar cells and mucins. </plain></SENT>
<SENT sid="5" pm="."><plain>Although the pathogenetic link between mucins and lung fibrosis is not known, it is possible that MUC5B overexpression interferes with physiological mucosal host defense, with reduced clearance of micro-organisms or inorganic noxious agents, or induction of endoplasmic reticulum stress. </plain></SENT>
<SENT sid="6" pm="."><plain>Other components of innate and adaptive immunity are likely to be involved in IPF pathogenesis/progression. </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, the importance of the clotting cascade in IPF pathogenesis has been confirmed by a recent epidemiological study, in which patients with IPF were almost five times more likely than general population controls to have at least one inherited or acquired clotting defect. </plain></SENT>
</text></SecTag></p></abstract></article-meta><notes><p>The electronic version of this article is the complete one and can be found at: <ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/reports/m/6/69">http://f1000.com/prime/reports/m/6/69</ext-link></p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s01"><title><text><SENT sid="8" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="9" pm="."><plain>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease limited to the lungs, occurring in older individuals, more frequently men, and characterized by a dismal prognosis, with a median survival of 3 to 5 years since diagnosis, although a wide variability in disease course is increasingly recognized. </plain></SENT>
<SENT sid="10" pm="."><plain>According to the more commonly held and current pathogenetic model, IPF results from recurrent injury to epithelial cells caused by a variety of exposures. </plain></SENT>
<SENT sid="11" pm="."><plain>These include cigarette smoke, dusts, and other environmental agents, which, in a genetically predisposed individual, lead to activation of abnormal pathways, resulting in failed resolution of the wound-healing response. </plain></SENT>
<SENT sid="12" pm="."><plain>This article does not aim to provide an exhaustive review of pathogenetic pathways in IPF, but rather will focus on selected topics, in particular on contributions to the understanding of IPF pathogenesis provided by recent genetic association studies, and other selected data and hypotheses. </plain></SENT>
</text></p></sec></SecTag><sec id="s02"><title><text><SENT sid="13" pm="."><plain>Genetic studies </plain></SENT>
</text></title><p><text><SENT sid="14" pm="."><plain>Genetic predisposition to IPF is supported by familial clustering, the occurrence of lung fibrosis in genetic multi-system disorders, and differing susceptibilities in humans exposed to similar levels of fibrogenic agents. </plain></SENT>
<SENT sid="15" pm="."><plain>Genetic association studies are useful in identifying relevant molecules/cell types among the wide array of potential pathogenetic pathways and can highlight otherwise unexpected areas. </plain></SENT>
</text></p><sec id="s02_1"><title><text><SENT sid="16" pm="."><plain>The role of type II cells </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>Mutations in the genes for surfactant protein C (SFTPC) and surfactant protein A2 (SFTPA2) have been described in association with familial lung fibrosis [1,2] and rarely with sporadic IPF [3,4]. </plain></SENT>
<SENT sid="18" pm="."><plain>Although they account for only approximately 1% of familial cases, the fact that both surfactant proteins are exclusively synthesized by type II alveolar epithelial cells points to type II cell dysfunction as a key element in IPF. </plain></SENT>
<SENT sid="19" pm="."><plain>The relevance of type II cells is also suggested by the prognostic value of serum surfactant proteins in sporadic IPF and other interstitial lung diseases (ILDs) [5]. </plain></SENT>
<SENT sid="20" pm="."><plain>In addition to synthesizing surfactant proteins, type II alveolar cells are responsible for the constant regeneration of the alveolar epithelium, as precursors of the terminally differentiated type I cells. </plain></SENT>
<SENT sid="21" pm="."><plain>Surfactant protein C and A mutations have been shown to cause incorrect protein folding/processing, thereby activating the cell’s endoplasmic reticulum (ER) stress response. </plain></SENT>
<SENT sid="22" pm="."><plain>This is a stereotypical protective mechanism in response to the accumulation of misfolded proteins, ultimately leading to activation of apoptosis pathways [6,7]. </plain></SENT>
<SENT sid="23" pm="."><plain>Increased staining for markers of ER stress response and apoptosis is also observed in sporadic IPF [8,9], highlighting a prominent role for activation of the ER stress response and alveolar cell apoptosis in pathogenesis. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Type II cells are also affected in the Hermansky-Pudlak syndrome (HPS), a genetic disease frequently associated with lung fibrosis. </plain></SENT>
<SENT sid="25" pm="."><plain>HPS is caused by mutations in genes encoding for proteins involved in lysosome-related intracellular trafficking, leading to giant lamellar body formation in type II alveolar cells [10]. </plain></SENT>
<SENT sid="26" pm="."><plain>Although alveolar epithelial ER stress has been described in HPS lung fibrosis [11], Young and colleagues report that impaired intracellular trafficking pathways do not directly result in ER stress, suggesting further studies are needed to evaluate mechanisms [12]. </plain></SENT>
</text></p></sec><sec id="s02_2"><title><text><SENT sid="27" pm="."><plain>Telomere shortening </plain></SENT>
</text></title><p><text><SENT sid="28" pm="."><plain>Pulmonary fibrosis occurs in a subset of patients with dyskeratosis congenita, a rare genetic disorder. </plain></SENT>
<SENT sid="29" pm="."><plain>Rapidly dividing tissues are affected, including epithelial cells and bone marrow, secondary to mutations in genes encoding for telomerase enzyme components. </plain></SENT>
<SENT sid="30" pm="."><plain>Telomerases are responsible for the elongation of telomeres, repetitive DNA sequences capping chromosome ends. </plain></SENT>
<SENT sid="31" pm="."><plain>Telomeres shorten at each cell replication until a critical length is reached, triggering a DNA damage response, leading to cellular senescence or apoptosis. </plain></SENT>
<SENT sid="32" pm="."><plain>Loss of telomerase activity reduces the renewal potential of stem cell populations [13]. </plain></SENT>
<SENT sid="33" pm="."><plain>Rare mutations in the telomerase genes TERT and TERC have been identified in approximately 8% of familial cases and in 1% to 3% of sporadic cases [14,15]. </plain></SENT>
<SENT sid="34" pm="."><plain>Telomeres shorten with age, and telomere dysfunction may be involved in a number of age-related degenerative disorders [16]. </plain></SENT>
<SENT sid="35" pm="."><plain>Even in the absence of TERT/TERC mutations, a proportion of IPF patients have shorter telomeres compared with age-matched controls [17,18]. </plain></SENT>
<SENT sid="36" pm="."><plain>In aggregate, these findings suggest that IPF may be a disease of accelerated aging in the lung, at least in the subset characterized by shortened telomeres. </plain></SENT>
<SENT sid="37" pm="."><plain>However, shorter telomeres in circulating leukocytes compared with age-matched control populations are also observed in chronic obstructive pulmonary disease (COPD), in asthma, and in association with lower lung function in control individuals, suggesting that the phenomenon of premature aging is not specific to pulmonary fibrosis [19]. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>The mechanisms through which telomere/telomerase defects may lead to pulmonary fibrosis are not well known. </plain></SENT>
<SENT sid="39" pm="."><plain>As telomerase dysfunction is most likely to affect cells with high turnover, epithelial cells are obvious candidates. </plain></SENT>
<SENT sid="40" pm="."><plain>Indeed, IPF alveolar epithelium had shorter telomeres than normal control epithelium, independently of detectable telomerase mutations in one study [17], although further studies are needed to confirm this interesting observation. </plain></SENT>
<SENT sid="41" pm="."><plain>Telomerase activity may differ according to cell type as increased telomerase activity has been reported in IPF lung fibroblasts, which is in keeping with potential increased survival and resistance to apoptosis in these cells [20]. </plain></SENT>
</text></p></sec><sec id="s02_3"><title><text><SENT sid="42" pm="."><plain>Bronchiolar cells </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>A prominent role for activated bronchiolar-type epithelial cells was first proposed by Chilosi and colleagues, in a study reporting activation of the Wnt/beta-catenin/matrylisin developmental pathway in hyperplastic bronchiolar lesions [21]. </plain></SENT>
<SENT sid="44" pm="."><plain>This was a feature seen in IPF but not in other ILD patterns, in contrast with nuclear beta-catenin expression observed in type II pneumocytes across ILDs. </plain></SENT>
<SENT sid="45" pm="."><plain>A particularly strong beta-catenin staining in areas of bronchiolization was confirmed by Konigshoff and colleagues [22]. </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>In genetic studies, a role for bronchiolar cells has been suggested by the finding of a marked increase in a MUC5B gene common promoter polymorphism in familial interstitial pneumonia (FIP) and sporadic IPF compared with controls (minor allele present in 33.8% of FIP cases, 37.5% of sporadic IPF cases, and 9.1% of control subjects) [23,24]. </plain></SENT>
<SENT sid="47" pm="."><plain>This strong association suggests the pathogenetic significance of mucins/small airways in IPF. </plain></SENT>
<SENT sid="48" pm="."><plain>By contrast, no association was found between MUC5B and scleroderma-associated lung fibrosis or with fibrotic sarcoidosis, suggesting that this association may be specific to the idiopathic ILDs [25,26]. </plain></SENT>
</text></p><p><text><SENT sid="49" pm="."><plain>Although the MUC5B variants are associated with overexpression in lung tissue compared with non-carriers in control subjects, this is not the case in IPF, where lung MUC5B overexpression is seen independently of genetic variants [23]. </plain></SENT>
<SENT sid="50" pm="."><plain>This observation suggests that, in the absence of (or in addition to) MUC5B genetic variation, other environmental or genetic factors (or both) linked to disease pathogenesis cause its upregulation. </plain></SENT>
<SENT sid="51" pm="."><plain>MUC5B appears to localize mainly to the distal airways and to the honeycomb cysts in what appear to be bronchiolar cells rather than type II alveolar cells [27]. </plain></SENT>
<SENT sid="52" pm="."><plain>Honeycombing lesions would therefore derive from the dilatation of the small airways, an observation that was originally made more than 50 years ago [28]. </plain></SENT>
<SENT sid="53" pm="."><plain>The mucin-producing cells in the honeycombed areas are characterized by a transcription factor and mucin profile suggestive of abnormal programming, with a phenotype similar to that of submucosal gland goblet cells, normally not found in the distal airspaces [29]. </plain></SENT>
<SENT sid="54" pm="."><plain>The mechanism by which MUC5B polymorphisms predispose individuals to pulmonary fibrosis is not known. </plain></SENT>
<SENT sid="55" pm="."><plain>One of the hypotheses is that MUC5B variants may lead to impaired clearance of inhaled micro-organisms and other particles and therefore an aberrant innate response, although a direct toxic effect on epithelial cells and/or ectopic expression with intracellular accumulation and resulting ER stress response are also possibilities [23,30]. </plain></SENT>
</text></p><p><text><SENT sid="56" pm="."><plain>Interestingly, while MUC5B overexpression is associated with IPF independently of the genetic polymorphisms, the MUC5B genetic variant actually appears to be associated with slower progression and better survival [26,31], suggesting that it marks a subset of the disease. </plain></SENT>
<SENT sid="57" pm="."><plain>There is a known variability in the clinical course of IPF, ranging from prolonged stability/gradual worsening to rapid stepwise progression [32–34]. </plain></SENT>
<SENT sid="58" pm="."><plain>Disease subsets are also suggested by a recent whole-genome expression analysis in a large number of IPF biopsies [35]. </plain></SENT>
<SENT sid="59" pm="."><plain>Clustering of the genes differentially expressed compared with controls reveals a separation into two clear IPF subpopulations, based on a distinct molecular signature. </plain></SENT>
<SENT sid="60" pm="."><plain>One IPF group is characterized by overexpression (compared with the other) of a number of genes already known to be upregulated in IPF, including osteopontin, matrix metalloprotease 1 (MMP1), MMP7, and MUC5B. </plain></SENT>
<SENT sid="61" pm="."><plain>The same IPF group is also characterized by upregulation of a large number of transcripts associated with cilium genes. </plain></SENT>
<SENT sid="62" pm="."><plain>These include structural components such as axonemal dyneins involved in ciliary motility as well as transcription factors regulating cilium gene expression, including RFX3, FOXJ1, and RFX2. </plain></SENT>
<SENT sid="63" pm="."><plain>Patients with high cilium gene expression demonstrate more microscopic honeycombing but not more fibroblastic foci on lung biopsy [35]. </plain></SENT>
<SENT sid="64" pm="."><plain>These observations reinforce the role played by airway cells (at least in a subset) and for the first time provide molecular evidence that IPF may in fact consist of more than one disease, each with likely different pathogenesis, prognosis, and treatment responses. </plain></SENT>
<SENT sid="65" pm="."><plain>The authors do not mention whether these two subsets separate out according to the MUC5B polymorphisms or whether they are characterized by different longitudinal behavior, and no doubt further studies will shed light on this. </plain></SENT>
</text></p><p><text><SENT sid="66" pm="."><plain>Two recent large genome-wide case-control association studies have confirmed the association with MUC5B [36,37], with the study by Fingerlin and colleagues [36] also identifying associations with common variants in the TERT and TERC genes. </plain></SENT>
<SENT sid="67" pm="."><plain>Both studies also report associations with several novel common gene variants. </plain></SENT>
<SENT sid="68" pm="."><plain>Among these, Fingerlin and colleagues report an association with genes involved in epithelial integrity and cell-cell adhesion, including desmoplakin (DSP) and DPP9, suggesting that defects in cell-cell adhesion or cellular cytoskeleton (or both) could predispose patients to injury in response to stimuli, including mechanical stretch. </plain></SENT>
<SENT sid="69" pm="."><plain>Both studies report an association with TOLLIP, a regulator of innate immune responses involved in modulating Toll-like receptor (TLR) signaling. </plain></SENT>
<SENT sid="70" pm="."><plain>The TOLLIP gene resides close to MUC5B, and variants in the two genes are in weak linkage disequilibrium. </plain></SENT>
<SENT sid="71" pm="."><plain>Once the MUC5B variants were included in the analysis, the association with the TOLLIP gene single-nucleotide polymorphisms (SNPs) only just reached statistical significance in the study by Noth and colleagues [37] (P = 0.05) and was no longer significant in the study by Fingerlin and colleagues, indicating the need for further studies. </plain></SENT>
<SENT sid="72" pm="."><plain>Interestingly, the minor allele of one of the TOLLIP SNPs (rs5743890) found to be protective toward lung fibrosis was associated with worse survival. </plain></SENT>
<SENT sid="73" pm="."><plain>This finding was maintained on adjusting for other gene variants, although MUC5B was not included in the multivariate analysis [37]. </plain></SENT>
<SENT sid="74" pm="."><plain>Again, whether the TOLLIP variant is a prognostic determinant, independently of MUC5B, remains to be determined. </plain></SENT>
</text></p></sec></sec><sec id="s03"><title><text><SENT sid="75" pm="."><plain>Gene expression and epigenetic regulation </plain></SENT>
</text></title><p><text><SENT sid="76" pm="."><plain>Transcriptional profiling studies of fibrotic lung tissues have identified key differences with control tissues and between different fibrotic ILD patterns [38–41]. </plain></SENT>
<SENT sid="77" pm="."><plain>Matrilysin (MMP7), one of the downstream targets of Wnt/beta-catenin, is highly overexpressed in IPF biopsies [38] and has been investigated as a peripheral blood biomarker in ILD. </plain></SENT>
<SENT sid="78" pm="."><plain>In the largest prospective biomarker study performed so far in IPF, MMP7, together with intercellular adhesion molecule-1 (ICAM-1) and interleukin-8 (IL-8), was the strongest predictor of survival in combination with clinical characteristics [42]. </plain></SENT>
<SENT sid="79" pm="."><plain>Boon and colleagues reported on upregulation in pathways involved in cell growth, proliferation, and migration in lung tissue from rapidly progressive compared with relatively stable IPF [43], suggesting that there may be common pathways between lung fibrosis and cancer development [44]. </plain></SENT>
<SENT sid="80" pm="."><plain>Rapidly progressive fibrosis was also characterized by upregulation of PLUNC, a molecule expressed mainly by secretory bronchial columnar cells, again highlighting a potential role for airway/innate defense functions [43]. </plain></SENT>
<SENT sid="81" pm="."><plain>With regard to fibroblasts, these are the main effector cell types involved in the fibrotic process [45], regardless of the initiating triggers. </plain></SENT>
<SENT sid="82" pm="."><plain>Gene expression profiling studies of cultured lung fibroblasts show specific pathways of activation [46–48], which appear to be similar in IPF and in scleroderma-associated ILD [48]. </plain></SENT>
</text></p><p><text><SENT sid="83" pm="."><plain>Although the study of epigenetic regulation in IPF is relatively recent, analysis in lung tissue or in IPF fibroblasts (or both) of the global and individual gene expression regulation through methylation [49–51], acetylation [52,53], and regulatory microRNAs [54–61] is providing information on regulatory networks and should allow a better understanding of how particular genetic variants and environmental exposures interact to cause pulmonary fibrosis, ultimately leading to novel treatment strategies. </plain></SENT>
</text></p></sec><sec id="s04"><title><text><SENT sid="84" pm="."><plain>Innate and adaptive immune responses </plain></SENT>
</text></title><p><text><SENT sid="85" pm="."><plain>The role played by conventional inflammation in IPF pathogenesis has been questioned, mainly in view of the lack of response to corticosteroids and immunosuppressants, which may indeed be harmful in patients with IPF [62]. </plain></SENT>
<SENT sid="86" pm="."><plain>However, components of the innate and adaptive immune response are thought to contribute to the pathogenesis of lung fibrosis. </plain></SENT>
</text></p><p><text><SENT sid="87" pm="."><plain>The innate immune system plays a crucial role in initiating and terminating inflammatory responses to endogenous and exogenous noxious stimuli. </plain></SENT>
<SENT sid="88" pm="."><plain>The alveolar macrophage is a potential source of chemokines and growth factors that regulate the wound-healing response. </plain></SENT>
<SENT sid="89" pm="."><plain>Macrophages are characterized by at least two phenotypes: M1, induced by Th1 cytokines such as interferon, and expressing IL-12, tumor necrosis factor (TNF), and C-X-C motif chemokine (CXCL)10, and M2 (or alternatively activated M), which expresses CD163, mannose receptors, and secretes increased levels of IL-10, chemokine (C-C motif) ligand (CCL)18, and CCL22 [63]. </plain></SENT>
<SENT sid="90" pm="."><plain>Two carefully conducted large prospective studies have shown that bronchoalveolar lavage (BAL) and serum levels of CCL18, one of the markers of M2 macrophages, are significantly linked to extent of fibrosis and predict likelihood of progression, even after adjustment for disease severity, both in IPF and in systemic sclerosis-ILD [64,65]. </plain></SENT>
</text></p><p><text><SENT sid="91" pm="."><plain>Pattern recognition receptors, including TLRs, recognize pathogen and endogenous patterns, activate innate and adaptive immune responses, and participate in regulating wound healing [66]. </plain></SENT>
<SENT sid="92" pm="."><plain>Pathogen-associated molecular patterns (PAMPs) are suspected to play a role in the activation of fibroblasts through TLRs as well as nucleotide-binding oligomerization domain-like receptors (NLR)s and retinoic acid-inducible gene-1 (RIG-1) receptors [67]. </plain></SENT>
<SENT sid="93" pm="."><plain>Endogenous ligands can also be identified by TLRs, including components of the extracellular matrix such as hyaluronic acid [68], and fibrinogen degradation products [69]. </plain></SENT>
<SENT sid="94" pm="."><plain>Interestingly, the ligation of the latter to TLR4 has been shown to induce upregulation of mucin MUC5AC expression in both alveolar macrophages and epithelial cells [69]. </plain></SENT>
</text></p><p><text><SENT sid="95" pm="."><plain>TLR9 expression has been found to be increased in ILD lung tissue and in IPF fibroblasts compared with control subjects [70,71]. </plain></SENT>
<SENT sid="96" pm="."><plain>In particular, in both usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP), the increased expression is localized to areas of fibrosis in the epithelium and interstitium [70]. </plain></SENT>
<SENT sid="97" pm="."><plain>TLR9 activation by hypomethylated DNA significantly increased alpha smooth muscle actin [70] and promoted profibrotic cytokine and chemokine synthesis in IPF fibroblasts in culture [72]. </plain></SENT>
<SENT sid="98" pm="."><plain>TLR9 was particularly upregulated in the lung tissues of rapidly progressive IPF compared with more stable disease [73]. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>TLR3 has been shown to act as a sensor of tissue necrosis during acute inflammation. </plain></SENT>
<SENT sid="100" pm="."><plain>In addition, it recognizes virus-associated molecular patterns and activates pro-inflammatory cascades [74,75]. </plain></SENT>
<SENT sid="101" pm="."><plain>Recently, a TLR3 polymorphism (TLR3L412F) associated with defective function of the receptor was studied in patients with IPF. </plain></SENT>
<SENT sid="102" pm="."><plain>Fibroblasts homozygous for the variant allele had an impaired interferon-beta response, displaying enhanced proliferation after TLR3 stimulation, partially corrected after interferon-beta treatment. </plain></SENT>
<SENT sid="103" pm="."><plain>Furthermore, the variant was associated with disease progression or early mortality (or both) in two separate IPF cohorts, with an additive effect for each allele [76]. </plain></SENT>
<SENT sid="104" pm="."><plain>This study is another example of a genetic variant linked to outcome in IPF and highlights the possibility of differences in response to treatments in different subsets, as suggested by the editorial accompanying the article [77]. </plain></SENT>
<SENT sid="105" pm="."><plain>The activation of TLRs in epithelial and interstial cells could be one of the links between exogenous/endogenous noxious signals and amplification of immune and fibroproliferative responses. </plain></SENT>
<SENT sid="106" pm="."><plain>Further studies are needed to assess their role in the pathogenesis of pulmonary fibrosis. </plain></SENT>
</text></p><p><text><SENT sid="107" pm="."><plain>Adaptive immunity is also likely to be involved in IPF progression. </plain></SENT>
<SENT sid="108" pm="."><plain>We know that in hypersensitivity pneumonitis (HP) adaptive immunity is a crucial driver of disease. </plain></SENT>
<SENT sid="109" pm="."><plain>A proportion of patients with fibrotic HP have a UIP histology and can display an IPF-like disease course [78], although features such as airway centeredness of fibrosis and excess inflammation suggest the diagnosis of HP-associated UIP [79]. </plain></SENT>
<SENT sid="110" pm="."><plain>There may be at least a subset of patients with IPF in whom the fibrotic response is a response to an unknown antigen, with a role played by adaptive immunity. </plain></SENT>
<SENT sid="111" pm="."><plain>Indeed, Gilani and colleagues found that increased proportions of circulating CD28nullCD4+ T cells are associated with poor outcomes in patients with IPF [80]. </plain></SENT>
<SENT sid="112" pm="."><plain>CD28nullCD4+ cells are effector memory T cells, which develop as a result of repeated antigen-driven proliferations. </plain></SENT>
<SENT sid="113" pm="."><plain>These cells display increased production of cytotoxic mediators and pro-inflammatory cytokines, in keeping with enhanced noxious potential. </plain></SENT>
<SENT sid="114" pm="."><plain>Interestingly, CD28null T-cell telomeres are shortened as a result of repetitive T-cell clonal proliferations [81], and T cells comprise 40% to 50% of peripheral blood monocytes. </plain></SENT>
<SENT sid="115" pm="."><plain>This could contribute to findings of telomere shortening in the peripheral blood leukocytes of IPF patients and other populations with chronic disease. </plain></SENT>
<SENT sid="116" pm="."><plain>The relevance of T-cell differentiation in IPF, again as a result of repetitive antigen stimulation, is also supported by a recent report by Herazo-Maya and colleagues [82]. </plain></SENT>
<SENT sid="117" pm="."><plain>BAL and lung tissue-activated CD4+ T cells are observed in asymptomatic early familial ILD cases [83], and pro-inflammatory dendritic cells are found in advanced lung fibrosis [84]. </plain></SENT>
<SENT sid="118" pm="."><plain>In IPF lungs, CD8+ T lymphocytes correlated with degree of breathlessness and functional severity [85]. </plain></SENT>
<SENT sid="119" pm="."><plain>IPF lung-derived proteins induce proliferation of autologous CD4 T cells from these patients [86]. </plain></SENT>
<SENT sid="120" pm="."><plain>Semaphorin 7a+ regulatory T cells are increased in the blood of patients with rapidly progressive IPF [87]. </plain></SENT>
</text></p><p><text><SENT sid="121" pm="."><plain>In addition to T cells, B cells may also be involved in IPF pathogenesis. </plain></SENT>
<SENT sid="122" pm="."><plain>Auto-antibodies against heat shock protein 70 (HSP 70) are associated with short-term deterioration in patients with IPF, independently of disease severity, suggesting a potential link to a pathogenetically significant process [88]. </plain></SENT>
<SENT sid="123" pm="."><plain>The finding of lymphoid follicles in IPF biopsies has been reported in a number of studies [89-91]. </plain></SENT>
<SENT sid="124" pm="."><plain>The presence of B-cell aggregates in injured tissues suggests a possible direct contribution of the significant pathogenetic potential of B cells to the fibrotic process [92]. </plain></SENT>
<SENT sid="125" pm="."><plain>Xue and colleagues observed an increase in circulating antigen-differentiated plasma cells in IPF patients and overexpression of a specific B-cell trophic factor (plasma B lymphocyte-stimulating factor), associated with poor short-term outcome [90]. </plain></SENT>
<SENT sid="126" pm="."><plain>A chemokine that mediates B-cell trafficking, CXCL13, was increased in the lung tissue and peripheral blood of IPF patients compared with healthy controls and COPD patients and was predictive of early mortality, further supporting a pathogenetic role for B cells [93]. </plain></SENT>
</text></p><p><text><SENT sid="127" pm="."><plain>It seems likely that both the innate and adaptive immune systems participate in lung fibrosis progression. </plain></SENT>
<SENT sid="128" pm="."><plain>However, the question of whether the hyperstimulation of the immune system described above is directly causative of lung fibrosis rather than a consequence of the loss of the normal lung architecture and therefore of natural defenses is more difficult to resolve. </plain></SENT>
<SENT sid="129" pm="."><plain>We should also consider the possibility of an interaction between the different pathogenetic mechanisms. </plain></SENT>
<SENT sid="130" pm="."><plain>For example, Agrawal and colleagues recently observed that an interaction between surfactant protein (SP)-A and TLR2 is involved in regulating secretion of pro-inflammatory mediators in macrophage lines both in vitro and in vivo [94]. </plain></SENT>
</text></p></sec><sec id="s05"><title><text><SENT sid="131" pm="."><plain>The clotting cascade </plain></SENT>
</text></title><p><text><SENT sid="132" pm="."><plain>The clotting cascade appears to be activated in pulmonary fibrosis, as suggested by in vitro and animal model studies [95]. </plain></SENT>
<SENT sid="133" pm="."><plain>Cleaved clotting factors have major pro-inflammatory and profibrogenic effects [96], and activated platelets/endothelial cells release fibrogenic mediators, including platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGFβ) [97]. </plain></SENT>
<SENT sid="134" pm="."><plain>Navaratnam and colleagues recently reported on a carefully conducted case-control study of 211 incident IPF cases to evaluate the incidence of clotting abnormalities identified through a pro-thrombotic panel of 11 clotting defects [98]. </plain></SENT>
<SENT sid="135" pm="."><plain>The authors found that patients with IPF have an almost fivefold greater chance of having at least one clotting abnormality, with incrementally increasing odds ratios for increasing numbers of clotting abnormalities. </plain></SENT>
<SENT sid="136" pm="."><plain>The highest odds ratios were seen for elevation of factor VIII levels (&gt;165 IU/dL in 124 out of 194 patients with IPF versus 45 out of 211 controls). </plain></SENT>
<SENT sid="137" pm="."><plain>Furthermore, clotting abnormalities were associated with more severe disease at baseline and a worse survival. </plain></SENT>
<SENT sid="138" pm="."><plain>How this fits with the recent trial of warfarin treatment in IPF, which was stopped early because of an increased rate of pulmonary fibrosis deterioration in the warfarin-treated arm [99], will need to be further investigated, but it does support previous studies pointing to an important role played by the coagulation system in the lung fibrosis process. </plain></SENT>
</text></p></sec><sec id="s06"><title><text><SENT sid="139" pm="."><plain>Physical factors </plain></SENT>
</text></title><p><text><SENT sid="140" pm="."><plain>Leslie recently proposed a unifying hypothesis for IPF as a disease of “recurrent stretch injury to the peripheral and basal lung occurring over many years in predisposed individuals” [100]. </plain></SENT>
<SENT sid="141" pm="."><plain>This theory attempts to reconcile a number of unexplained features, including the predominantly basal and subpleural distribution, the progression of the disease toward the apical regions, and the finding that fibroblastic foci are a continuum extending inward from the pleural surface (fibroblastic reticulum) [101]. </plain></SENT>
<SENT sid="142" pm="."><plain>IPF would start in the basal and peripheral regions of the lungs, where the alveoli are the smallest in the upright and supine positions and are therefore more likely to collapse in response to the tractional forces during respiration, as also suggested by Galvin and colleagues [102] and Dail [103]. </plain></SENT>
<SENT sid="143" pm="."><plain>Surfactant protein abnormalities could lead to increased surface tension and greater likelihood of alveolar collapse, while the reticular network of fibroblastic foci would occur along stress fractures/lines at the interface between the epithelium and the mesenchymal cells. </plain></SENT>
<SENT sid="144" pm="."><plain>A vicious circle of increasing alveolar surface tension causing further alveolar collapse and subsequent enlargement of the alveolar ducts leading to microscopic honeycombing would follow. </plain></SENT>
<SENT sid="145" pm="."><plain>Carloni and colleagues applied a mathematical model to verify whether the distribution of IPF lesions corresponds to the areas of greatest mechanical tension [104]. </plain></SENT>
<SENT sid="146" pm="."><plain>If these mechanical forces have a role in the origin or in the progression of the disease, they should also influence those cases with associated emphysema, which were initially described more than 20 years ago [105] and which only recently have attracted the attention of researchers [106]. </plain></SENT>
<SENT sid="147" pm="."><plain>In these cases, one would expect a lower traction in the basal zones because of reduced elastic recoil of the upper parts of the lung. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec sec-type="conclusions" id="s07"><title><text><SENT sid="148" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="149" pm="."><plain>In conclusion, genetic association studies suggest a pivotal pathogenetic role played by abnormal regeneration/differentiation potential of respiratory epithelial cells in IPF (both alveolar and bronchiolar), which is likely to be determined by the interaction between environmental exposures such as cigarette smoke and gene variants, including surfactant protein and telomerase genes. </plain></SENT>
<SENT sid="150" pm="."><plain>The association with MUC5B suggests a role of airway epithelial cells and mucins. </plain></SENT>
<SENT sid="151" pm="."><plain>Further studies on how molecular phenotypes can be linked in to genetic data and to clinical, radiological, and histological characteristics of the disease will be crucial to predict clinical course and drive novel treatments in IPF. </plain></SENT>
</text></p></sec></SecTag></body><back><notes><sec><title>Disclosures</title><p>The authors declare that they have no disclosures.</p></sec></notes><SecTag type="REF"><ref-list><title>References</title><ref id="bib-001"><text><SENT sid="152" pm="."><plain>1NogeeLMDunbarAEWertSEAskinFHamvasAWhitsettJAA mutation in the surfactant protein C gene associated with familial interstitial lung diseaseN Engl J Med2001344573910.1056/NEJM200102223440805<?supplied-pmid 11207353?>11207353<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489778">http://f1000.com/prime/718489778</ext-link> </plain></SENT>
</text></ref><ref id="bib-002"><text><SENT sid="153" pm="."><plain>2ThomasAQLaneKPhillipsJPrinceMMarkinCSpeerMSchwartzDAGaddipatiRMarneyAJohnsonJRobertsRHainesJStahlmanMLoydJEHeterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindredAm J Respir Crit Care Med20021651322810.1164/rccm.200112-123OC<?supplied-pmid 11991887?>11991887<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489779">http://f1000.com/prime/718489779</ext-link> </plain></SENT>
</text></ref><ref id="bib-003"><text><SENT sid="154" pm="."><plain>3MarkartPRuppertCWygreckaMSchmidtRKorfeiMHarbachHTheruvathIPisonUSeegerWGuentherAWittHSurfactant protein C mutations in sporadic forms of idiopathic interstitial pneumoniasEur Respir J200729134710.1183/09031936.00034406<?supplied-pmid 17005585?>17005585<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489780">http://f1000.com/prime/718489780</ext-link> </plain></SENT>
</text></ref><ref id="bib-004"><text><SENT sid="155" pm="."><plain>4LawsonWEGrantSWAmbrosiniVWombleKEDawsonEPLaneKBMarkinCRenzoniELympanyPThomasAQRoldanJScottTABlackwellTSPhillipsJALoydJEdu BoisRMGenetic mutations in surfactant protein C are a rare cause of sporadic cases of IPFThorax2004599778010.1136/thx.2004.026336<?supplied-pmid 15516475?>15516475 </plain></SENT>
</text></ref><ref id="bib-005"><text><SENT sid="156" pm="."><plain>5ZhangYKaminskiNBiomarkers in idiopathic pulmonary fibrosisCurr Opin Pulm Med201218441610.1097/MCP.0b013e328356d03c<?supplied-pmid 22847105?>22847105 </plain></SENT>
</text></ref><ref id="bib-006"><text><SENT sid="157" pm="."><plain>6KaboreAFWangWJRussoSJBeersMFBiosynthesis of surfactant protein C: characterization of aggresome formation by EGFP chimeras containing propeptide mutants lacking conserved cysteine residuesJ Cell Sci2001114293302<?supplied-pmid 11148131?>11148131 </plain></SENT>
</text></ref><ref id="bib-007"><text><SENT sid="158" pm="."><plain>7MulugetaSNguyenVRussoSJMuniswamyMBeersMFA surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activationAm J Respir Cell Mol Biol2005325213010.1165/rcmb.2005-0009OC<?supplied-pmid 15778495?>15778495 </plain></SENT>
</text></ref><ref id="bib-008"><text><SENT sid="159" pm="."><plain>8LawsonWECrossnoPFPolosukhinVVRoldanJChengDLaneKBBlackwellTRXuCMarkinCWareLBMillerGGLoydJEBlackwellTSEndoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infectionAm J Physiol Lung Cell Mol Physiol2008294L11192610.1152/ajplung.00382.2007<?supplied-pmid 18390830?>18390830 </plain></SENT>
</text></ref><ref id="bib-009"><text><SENT sid="160" pm="."><plain>9KorfeiMRuppertCMahavadiPHennekeIMarkartPKochMLangGFinkLBohleRSeegerWWeaverTEGuentherAEpithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosisAm J Respir Crit Care Med20081788384610.1164/rccm.200802-313OC<?supplied-pmid 18635891?>18635891<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1145273">http://f1000.com/prime/1145273</ext-link> </plain></SENT>
</text></ref><ref id="bib-010"><text><SENT sid="161" pm="."><plain>10NakataniYNakamuraNSanoJInayamaYKawanoNYamanakaSMiyagiYNagashimaYOhbayashiCMizushimaMManabeTKurodaMYokoiTMatsubaraOInterstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytesVirchows Arch20004373041310.1007/s004280000241<?supplied-pmid 11037352?>11037352 </plain></SENT>
</text></ref><ref id="bib-011"><text><SENT sid="162" pm="."><plain>11MahavadiPKorfeiMHennekeILiebischGSchmitzGGochuicoBRMarkartPBellusciSSeegerWRuppertCGuentherAEpithelial stress and apoptosis underlie Hermansky-Pudlak syndrome-associated interstitial pneumoniaAm J Respir Crit Care Med20101822071910.1164/rccm.200909-1414OC<?supplied-pmid 20378731?>20378731 </plain></SENT>
</text></ref><ref id="bib-012"><text><SENT sid="163" pm="."><plain>12YoungLRGullemanPMBridgesJPWeaverTEDeutschGHBlackwellTSMcCormackFXThe alveolar epithelium determines susceptibility to lung fibrosis in Hermansky-Pudlak syndromeAm J Respir Crit Care Med201218610142410.1164/rccm.201207-1206OC<?supplied-pmid 23043085?>23043085<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/717965536">http://f1000.com/prime/717965536</ext-link> </plain></SENT>
</text></ref><ref id="bib-013"><text><SENT sid="164" pm="."><plain>13BatistaLuis FZPechMFZhongFLNguyenHNXieKTZaugAJCrarySMChoiJSebastianoVCherryAGiriNWernigMAlterBPCechTRSavageSAReijo PeraRenee AArtandiSETelomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cellsNature201147439940210.1038/nature10084<?supplied-pmid 21602826?>21602826 </plain></SENT>
</text></ref><ref id="bib-014"><text><SENT sid="165" pm="."><plain>14ArmaniosMYChenJJCoganJDAlderJKIngersollRGMarkinCLawsonWEXieMVultoIPhillipsJALansdorpPMGreiderCWLoydJETelomerase mutations in families with idiopathic pulmonary fibrosisN Engl J Med200735613172610.1056/NEJMoa066157<?supplied-pmid 17392301?>17392301<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489781">http://f1000.com/prime/718489781</ext-link> </plain></SENT>
</text></ref><ref id="bib-015"><text><SENT sid="166" pm="."><plain>15TsakiriKDCronkhiteJTKuanPJXingCRaghuGWeisslerJCRosenblattRLShayJWGarciaCKAdult-onset pulmonary fibrosis caused by mutations in telomeraseProc Natl Acad Sci USA20071047552710.1073/pnas.0701009104<?supplied-pmid 17460043?>17460043<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1083021">http://f1000.com/prime/1083021</ext-link> </plain></SENT>
</text></ref><ref id="bib-016"><text><SENT sid="167" pm="."><plain>16ArmaniosMBlackburnEHThe telomere syndromesNat Rev Genet20121369370410.1038/nrg3246<?supplied-pmid 22965356?>22965356 </plain></SENT>
</text></ref><ref id="bib-017"><text><SENT sid="168" pm="."><plain>17AlderJKChenJJLancasterLDanoffSSuSCoganJDVultoIXieMQiXTuderRMPhillipsJALansdorpPMLoydJEArmaniosMYShort telomeres are a risk factor for idiopathic pulmonary fibrosisProc Natl Acad Sci USA200810513051610.1073/pnas.0804280105<?supplied-pmid 18753630?>18753630<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1123109">http://f1000.com/prime/1123109</ext-link> </plain></SENT>
</text></ref><ref id="bib-018"><text><SENT sid="169" pm="."><plain>18CronkhiteJTXingCRaghuGChinKMTorresFRosenblattRLGarciaCKTelomere shortening in familial and sporadic pulmonary fibrosisAm J Respir Crit Care Med20081787293710.1164/rccm.200804-550OC<?supplied-pmid 18635888?>18635888<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1130834">http://f1000.com/prime/1130834</ext-link> </plain></SENT>
</text></ref><ref id="bib-019"><text><SENT sid="170" pm="."><plain>19AlbrechtESillanpääEKarraschSAlvesACCoddVHovattaIBuxtonJLNelsonCPBroerLHäggSManginoMWillemsenGSurakkaIFerreiraManuel ARAminNOostraBABäckmandHMPeltonenMSarnaSRantanenTSipiläSKorhonenTMaddenPamela AFGiegerCJörresRAHeinrichJBehrJHuberRMPetersAStrauchKTelomere length in circulating leukocytes is associated with lung function and diseaseEur Respir J2014439839210.1183/09031936.00046213<?supplied-pmid 24311771?>24311771 </plain></SENT>
</text></ref><ref id="bib-020"><text><SENT sid="171" pm="."><plain>20LiuTUllenbruchMYoung ChoiYYuHDingLXaubetAPeredaJFeghali-BostwickCABittermanPBHenkeCAPardoASelmanMPhanSHTelomerase and telomere length in pulmonary fibrosisAm J Respir Cell Mol Biol201349260810.1165/rcmb.2012-0514OC<?supplied-pmid 23526226?>23526226<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/717991917">http://f1000.com/prime/717991917</ext-link> </plain></SENT>
</text></ref><ref id="bib-021"><text><SENT sid="172" pm="."><plain>21ChilosiMPolettiVZamòALestaniMMontagnaLPiccoliPPedronSBertasoMScarpaAMurerBCancellieriAMaestroRSemenzatoGDoglioniCAberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosisAm J Pathol2003162149550210.1016/S0002-9440(10)64282-4<?supplied-pmid 12707032?>12707032<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489782">http://f1000.com/prime/718489782</ext-link> </plain></SENT>
</text></ref><ref id="bib-022"><text><SENT sid="173" pm="."><plain>22KönigshoffMBalsaraNPfaffEKramerMChrobakISeegerWEickelbergOFunctional Wnt signaling is increased in idiopathic pulmonary fibrosisPLoS ONE20083e214210.1371/journal.pone.0002142<?supplied-pmid 18478089?>18478089 </plain></SENT>
</text></ref><ref id="bib-023"><text><SENT sid="174" pm="."><plain>23SeiboldMAWiseALSpeerMCSteeleMPBrownKKLoydJEFingerlinTEZhangWGudmundssonGGroshongSDEvansCMGarantziotisSAdlerKBDickeyBFdu BoisRoland MYangIVHerronAKervitskyDTalbertJLMarkinCParkJCrewsALSliferSHAuerbachSRoyMGLinJHennessyCESchwarzMISchwartzDAA common MUC5B promoter polymorphism and pulmonary fibrosisN Engl J Med201136415031210.1056/NEJMoa1013660<?supplied-pmid 21506741?>21506741<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/10416956">http://f1000.com/prime/10416956</ext-link> </plain></SENT>
</text></ref><ref id="bib-024"><text><SENT sid="175" pm="."><plain>24ZhangYNothIGarciaJoe GNKaminskiNA variant in the promoter of MUC5B and idiopathic pulmonary fibrosisN Engl J Med20113641576710.1056/NEJMc1013504<?supplied-pmid 21506748?>21506748<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718020072">http://f1000.com/prime/718020072</ext-link> </plain></SENT>
</text></ref><ref id="bib-025"><text><SENT sid="176" pm="."><plain>25PeljtoALSteeleMPFingerlinTEHinchcliffMEMurphyEPodluskySCarnsMSchwarzMVargaJSchwartzDAThe pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosisChest20121421584810.1378/chest.12-0110<?supplied-pmid 22576636?>22576636 </plain></SENT>
</text></ref><ref id="bib-026"><text><SENT sid="177" pm="."><plain>26StockCJSatoHFonsecaCBanyaWinston ASMolyneauxPLAdamaliHRussellADentonCPAbrahamDJHansellDMNicholsonAGMaherTMWellsAULindahlGERenzoniEAMucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosisThorax2013684364110.1136/thoraxjnl-2012-201786<?supplied-pmid 23321605?>23321605 </plain></SENT>
</text></ref><ref id="bib-027"><text><SENT sid="178" pm="."><plain>27SeiboldMASmithRWUrbanekCGroshongSDCosgroveGPBrownKKSchwarzMISchwartzDAReynoldsSDThe idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epitheliumPLoS ONE20138e5865810.1371/journal.pone.0058658<?supplied-pmid 23527003?>23527003 </plain></SENT>
</text></ref><ref id="bib-028"><text><SENT sid="179" pm="."><plain>28HepplestonAGThe pathology of honeycomb lungThorax195611779310.1136/thx.11.2.77<?supplied-pmid 13337792?>13337792 </plain></SENT>
</text></ref><ref id="bib-029"><text><SENT sid="180" pm="."><plain>29PlantierLCrestaniBWertSEDehouxMZweytickBGuentherAWhitsettJAEctopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosisThorax201166651710.1136/thx.2010.151555<?supplied-pmid 21422041?>21422041<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/11278956">http://f1000.com/prime/11278956</ext-link> </plain></SENT>
</text></ref><ref id="bib-030"><text><SENT sid="181" pm="."><plain>30BoucherRCIdiopathic pulmonary fibrosis--a sticky businessN Engl J Med20113641560110.1056/NEJMe1014191<?supplied-pmid 21506745?>21506745 </plain></SENT>
</text></ref><ref id="bib-031"><text><SENT sid="182" pm="."><plain>31PeljtoALZhangYFingerlinTEMaSGarciaJoe GNRichardsTJSilveiraLJLindellKOSteeleMPLoydJEGibsonKFSeiboldMABrownKKTalbertJLMarkinCKossenKSeiwertSDMurphyENothISchwarzMIKaminskiNSchwartzDAAssociation between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosisJAMA20133092232910.1001/jama.2013.5827<?supplied-pmid 23695349?>23695349<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/11278956">http://f1000.com/prime/11278956</ext-link> </plain></SENT>
</text></ref><ref id="bib-032"><text><SENT sid="183" pm="."><plain>32LeyBCollardHRKingTEClinical course and prediction of survival in idiopathic pulmonary fibrosisAm J Respir Crit Care Med20111834314010.1164/rccm.201006-0894CI<?supplied-pmid 20935110?>20935110 </plain></SENT>
</text></ref><ref id="bib-033"><text><SENT sid="184" pm="."><plain>33KimDSCollardHRKingTEClassification and natural history of the idiopathic interstitial pneumoniasProc Am Thorac Soc200632859210.1513/pats.200601-005TK<?supplied-pmid 16738191?>16738191 </plain></SENT>
</text></ref><ref id="bib-034"><text><SENT sid="185" pm="."><plain>34SelmanMCarrilloGEstradaAMejiaMBecerrilCCisnerosJGaxiolaMPérez-PadillaRNavarroCRichardsTDauberJKingTEPardoAKaminskiNAccelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression patternPLoS ONE20072e48210.1371/journal.pone.0000482<?supplied-pmid 17534432?>17534432 </plain></SENT>
</text></ref><ref id="bib-035"><text><SENT sid="186" pm="."><plain>35YangIVColdrenCDLeachSMSeiboldMAMurphyELinJRosenRNeidermyerAJMcKeanDFGroshongSDCoolCCosgroveGPLynchDABrownKKSchwarzMIFingerlinTESchwartzDAExpression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosisThorax20136811142110.1136/thoraxjnl-2012-202943<?supplied-pmid 23783374?>23783374<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718021340">http://f1000.com/prime/718021340</ext-link> </plain></SENT>
</text></ref><ref id="bib-036"><text><SENT sid="187" pm="."><plain>36FingerlinTEMurphyEZhangWPeljtoALBrownKKSteeleMPLoydJECosgroveGPLynchDGroshongSCollardHRWoltersPJBradfordWZKossenKSeiwertSDdu BoisRoland MGarciaCKDevineMSGudmundssonGIsakssonHJKaminskiNZhangYGibsonKFLancasterLHCoganJDMasonWRMaherTMMolyneauxPLWellsAUMoffattMFGenome-wide association study identifies multiple susceptibility loci for pulmonary fibrosisNat Genet20134561320<?supplied-pmid 23583980?>23583980<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718000223">http://f1000.com/prime/718000223</ext-link> </plain></SENT>
</text></ref><ref id="bib-037"><text><SENT sid="188" pm="."><plain>37NothIZhangYMaSFloresCBarberMHuangYBroderickSMWadeMSHysiPScuirbaJRichardsTJJuan-GuardelaBMVijRHanMKMartinezFJKossenKSeiwertSDChristieJDNicolaeDKaminskiNGarciaJoe GNGenetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association studyLancet Respir Med2013130917<?supplied-pmid 24429156?>24429156<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718246330">http://f1000.com/prime/718246330</ext-link> </plain></SENT>
</text></ref><ref id="bib-038"><text><SENT sid="189" pm="."><plain>38ZuoFKaminskiNEuguiEAllardJYakhiniZBen-DorALolliniLMorrisDKimYDeLustroBSheppardDPardoASelmanMHellerRAGene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humansProc Natl Acad Sci USA2002996292710.1073/pnas.092134099<?supplied-pmid 11983918?>11983918 </plain></SENT>
</text></ref><ref id="bib-039"><text><SENT sid="190" pm="."><plain>39MuraMAnrakuMYunZMcRaeKLiuMWaddellTKSingerLGGrantonJTKeshavjeeSPerrotM deGene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosisChest20121416617310.1378/chest.11-0449<?supplied-pmid 21835902?>21835902<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718181549">http://f1000.com/prime/718181549</ext-link> </plain></SENT>
</text></ref><ref id="bib-040"><text><SENT sid="191" pm="."><plain>40SelmanMPardoABarreraLEstradaAWatsonSRWilsonKAzizNKaminskiNZlotnikAGene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitisAm J Respir Crit Care Med20061731889810.1164/rccm.200504-644OC<?supplied-pmid 16166619?>16166619<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/10145">http://f1000.com/prime/10145</ext-link> </plain></SENT>
</text></ref><ref id="bib-041"><text><SENT sid="192" pm="."><plain>41HsuEShiHJordanRMLyons-WeilerJPilewskiJMFeghali-BostwickCALung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertensionArthritis Rheum2011637839410.1002/art.30159<?supplied-pmid 21360508?>21360508 </plain></SENT>
</text></ref><ref id="bib-042"><text><SENT sid="193" pm="."><plain>42RichardsTJKaminskiNBaribaudFFlavinSBrodmerkelCHorowitzDLiKChoiJVugaLJLindellKOKlesenMZhangYGibsonKFPeripheral blood proteins predict mortality in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2012185677610.1164/rccm.201101-0058OC<?supplied-pmid 22016448?>22016448<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/13373041">http://f1000.com/prime/13373041</ext-link> </plain></SENT>
</text></ref><ref id="bib-043"><text><SENT sid="194" pm="."><plain>43BoonKBaileyNWYangJSteelMPGroshongSKervitskyDBrownKKSchwarzMISchwartzDAMolecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF)PLoS ONE20094e513410.1371/journal.pone.0005134<?supplied-pmid 19347046?>19347046<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489783">http://f1000.com/prime/718489783</ext-link> </plain></SENT>
</text></ref><ref id="bib-044"><text><SENT sid="195" pm="."><plain>44VancheriCCommon pathways in idiopathic pulmonary fibrosis and cancerEur Respir Rev2013222657210.1183/09059180.00003613<?supplied-pmid 23997054?>23997054 </plain></SENT>
</text></ref><ref id="bib-045"><text><SENT sid="196" pm="."><plain>45McAnultyRJFibroblasts and myofibroblasts: their source, function and role in diseaseInt J Biochem Cell Biol2007396667110.1016/j.biocel.2006.11.005<?supplied-pmid 17196874?>17196874 </plain></SENT>
</text></ref><ref id="bib-046"><text><SENT sid="197" pm="."><plain>46Emblom-CallahanMCChhinaMKShlobinOAAhmadSReeseESIyerEswar PRCoxDNBrennerRBurtonNAGrantGMNathanSDGenomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosisGenomics2010961344510.1016/j.ygeno.2010.04.005<?supplied-pmid 20451601?>20451601 </plain></SENT>
</text></ref><ref id="bib-047"><text><SENT sid="198" pm="."><plain>47BridgesRSKassDLohKGlackinCBorczukACGreenbergSGene expression profiling of pulmonary fibrosis identifies Twist1 as an antiapoptotic molecular “rectifier” of growth factor signalingAm J Pathol200917523516110.2353/ajpath.2009.080954<?supplied-pmid 19893041?>19893041 </plain></SENT>
</text></ref><ref id="bib-048"><text><SENT sid="199" pm="."><plain>48LindahlGEStockCJShi-WenXLeoniPSestiniPHowatSLBou-GhariosGNicholsonAGDentonCPGruttersJCMaherTMWellsAUAbrahamDJRenzoniEAMicroarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung diseaseRespir Res2013148010.1186/1465-9921-14-80<?supplied-pmid 23915349?>23915349 </plain></SENT>
</text></ref><ref id="bib-049"><text><SENT sid="200" pm="."><plain>49SandersYYAmbalavananNHalloranBZhangXLiuHCrossmanDKBrayMZhangKThannickalVJHagoodJSAltered DNA methylation profile in idiopathic pulmonary fibrosisAm J Respir Crit Care Med20121865253510.1164/rccm.201201-0077OC<?supplied-pmid 22700861?>22700861<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/717952703">http://f1000.com/prime/717952703</ext-link> </plain></SENT>
</text></ref><ref id="bib-050"><text><SENT sid="201" pm="."><plain>50RabinovichEIKapetanakiMGSteinfeldIGibsonKFPanditKVYuGYakhiniZKaminskiNGlobal methylation patterns in idiopathic pulmonary fibrosisPLoS ONE20127e3377010.1371/journal.pone.0033770<?supplied-pmid 22506007?>22506007<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/716197983">http://f1000.com/prime/716197983</ext-link> </plain></SENT>
</text></ref><ref id="bib-051"><text><SENT sid="202" pm="."><plain>51HuangSKFisherASScruggsAMWhiteESHogaboamCMRichardsonBCPeters-GoldenMHypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and miceAm J Pathol201017722455510.2353/ajpath.2010.100446<?supplied-pmid 20889571?>20889571 </plain></SENT>
</text></ref><ref id="bib-052"><text><SENT sid="203" pm="."><plain>52SandersYYTollefsbolTOVariscoBMHagoodJSEpigenetic regulation of thy-1 by histone deacetylase inhibitor in rat lung fibroblastsAm J Respir Cell Mol Biol201145162310.1165/rcmb.2010-0154OC<?supplied-pmid 20724553?>20724553 </plain></SENT>
</text></ref><ref id="bib-053"><text><SENT sid="204" pm="."><plain>53CowardWRWattsKFeghali-BostwickCAJenkinsGPangLRepression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosisMol Cell Biol20103028748610.1128/MCB.01527-09<?supplied-pmid 20404089?>20404089 </plain></SENT>
</text></ref><ref id="bib-054"><text><SENT sid="205" pm="."><plain>54OakSRMurrayLHerathASleemanMAndersonIJoshiADCoelhoALFlahertyKRToewsGBKnightDMartinezFJHogaboamCMA micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosisPLoS ONE20116e2125310.1371/journal.pone.0021253<?supplied-pmid 21712985?>21712985<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/11944957">http://f1000.com/prime/11944957</ext-link> </plain></SENT>
</text></ref><ref id="bib-055"><text><SENT sid="206" pm="."><plain>55YamadaMKuboHOtaCTakahashiTTandoYSuzukiTFujinoNMakiguchiTTakagiKSuzukiTIchinoseMThe increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cellsRespir Res2013149510.1186/1465-9921-14-95<?supplied-pmid 24063588?>24063588 </plain></SENT>
</text></ref><ref id="bib-056"><text><SENT sid="207" pm="."><plain>56Lino CardenasChristian LacksHenaouiISCourcotERoderburgCCauffiezCAubertSCopinMWallaertBGlowackiFDewaelesEMilosevicJMaurizioJTedrowJMarcetBLo-GuidiceJKaminskiNBarbryPLueddeTPerraisMMariBPottierNmiR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1PLoS Genet20139e100329110.1371/journal.pgen.1003291<?supplied-pmid 23459460?>23459460 </plain></SENT>
</text></ref><ref id="bib-057"><text><SENT sid="208" pm="."><plain>57YangSCuiHXieNIcyuzMBanerjeeSAntonyVBAbrahamEThannickalVJLiuGmiR-145 regulates myofibroblast differentiation and lung fibrosisFASEB J20132723829110.1096/fj.12-219493<?supplied-pmid 23457217?>23457217 </plain></SENT>
</text></ref><ref id="bib-058"><text><SENT sid="209" pm="."><plain>58PanditKVCorcoranDYousefHYarlagaddaMTzouvelekisAGibsonKFKonishiKYousemSASinghMHandleyDRichardsTSelmanMWatkinsSCPardoABen-YehudahABourosDEickelbergORayPBenosPVKaminskiNInhibition and role of let-7d in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2010182220910.1164/rccm.200911-1698OC<?supplied-pmid 20395557?>20395557 </plain></SENT>
</text></ref><ref id="bib-059"><text><SENT sid="210" pm="."><plain>59DakhlallahDBatteKWangYCantemir-StoneCZYanPNuovoGMikhailAHitchcockCLWrightVPNana-SinkamSPPiperMGMarshCBEpigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosisAm J Respir Crit Care Med201318739740510.1164/rccm.201205-0888OC<?supplied-pmid 23306545?>23306545 </plain></SENT>
</text></ref><ref id="bib-060"><text><SENT sid="211" pm="."><plain>60PanditKVMilosevicJKaminskiNMicroRNAs in idiopathic pulmonary fibrosisTransl Res2011157191910.1016/j.trsl.2011.01.012<?supplied-pmid 21420029?>21420029 </plain></SENT>
</text></ref><ref id="bib-061"><text><SENT sid="212" pm="."><plain>61HogaboamCMMurrayLMartinezFJEpigenetic mechanisms through which Toll-like receptor-9 drives idiopathic pulmonary fibrosis progressionProc Am Thorac Soc20129172610.1513/pats.201201-002AW<?supplied-pmid 22802293?>22802293 </plain></SENT>
</text></ref><ref id="bib-062"><text><SENT sid="213" pm="."><plain>62RaghuGAnstromKJKingTELaskyJAMartinezFJPrednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosisN Engl J Med201236619687710.1056/NEJMoa1113354<?supplied-pmid 22607134?>22607134<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/716097808">http://f1000.com/prime/716097808</ext-link> </plain></SENT>
</text></ref><ref id="bib-063"><text><SENT sid="214" pm="."><plain>63MantovaniASozzaniSLocatiMAllavenaPSicaAMacrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytesTrends Immunol2002235495510.1016/S1471-4906(02)02302-5<?supplied-pmid 12401408?>12401408 </plain></SENT>
</text></ref><ref id="bib-064"><text><SENT sid="215" pm="."><plain>64PrasseAProbstCBargagliEZisselGToewsGBFlahertyKROlschewskiMRottoliPMüller-QuernheimJSerum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosisAm J Respir Crit Care Med20091797172310.1164/rccm.200808-1201OC<?supplied-pmid 19179488?>19179488<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1161000">http://f1000.com/prime/1161000</ext-link> </plain></SENT>
</text></ref><ref id="bib-065"><text><SENT sid="216" pm="."><plain>65TievKPHua-HuyTKettanehAGainMDuong-QuySTolédanoCCabaneJDinh-XuanATSerum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosisEur Respir J20113813556010.1183/09031936.00004711<?supplied-pmid 21778167?>21778167<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489784">http://f1000.com/prime/718489784</ext-link> </plain></SENT>
</text></ref><ref id="bib-066"><text><SENT sid="217" pm="."><plain>66HuebenerPSchwabeRFRegulation of wound healing and organ fibrosis by toll-like receptorsBiochim Biophys Acta20131832100517<?supplied-pmid 23220258?>23220258 </plain></SENT>
</text></ref><ref id="bib-067"><text><SENT sid="218" pm="."><plain>67KawaiTAkiraSThe roles of TLRs, RLRs and NLRs in pathogen recognitionInt Immunol2009213173710.1093/intimm/dxp017<?supplied-pmid 19246554?>19246554 </plain></SENT>
</text></ref><ref id="bib-068"><text><SENT sid="219" pm="."><plain>68ScheibnerKALutzMABoodooSFentonMJPowellJDHortonMRHyaluronan fragments act as an endogenous danger signal by engaging TLR2J Immunol200617712728110.4049/jimmunol.177.2.1272<?supplied-pmid 16818787?>16818787 </plain></SENT>
</text></ref><ref id="bib-069"><text><SENT sid="220" pm="."><plain>69MillienVOLuWShawJYuanXMakGRobertsLSongLKnightJMCreightonCJLuongAKheradmandFCorryDBCleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4Science2013341792610.1126/science.1240342<?supplied-pmid 23950537?>23950537<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718078457">http://f1000.com/prime/718078457</ext-link> </plain></SENT>
</text></ref><ref id="bib-070"><text><SENT sid="221" pm="."><plain>70MeneghinAChoiESEvanoffHLKunkelSLMartinezFJFlahertyKRToewsGBHogaboamCMTLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiationHistochem Cell Biol20081309799210.1007/s00418-008-0466-z<?supplied-pmid 18633634?>18633634<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489785">http://f1000.com/prime/718489785</ext-link> </plain></SENT>
</text></ref><ref id="bib-071"><text><SENT sid="222" pm="."><plain>71MargaritopoulosGAAntoniouKMKaragiannisKSamaraKDLasithiotakiIVassalouELymbouridouRKoutalaHSiafakasNMInvestigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage studyFibrogenesis Tissue Repair2010320<?supplied-pmid 20937083?>20937083<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489786">http://f1000.com/prime/718489786</ext-link> </plain></SENT>
</text></ref><ref id="bib-072"><text><SENT sid="223" pm="."><plain>72HogaboamCMTrujilloGMartinezFJAberrant innate immune sensing leads to the rapid progression of idiopathic pulmonary fibrosisFibrogenesis Tissue Repair20125Suppl 1S3<?supplied-pmid 23259678?>23259678<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489787">http://f1000.com/prime/718489787</ext-link> </plain></SENT>
</text></ref><ref id="bib-073"><text><SENT sid="224" pm="."><plain>73TrujilloGMeneghinAFlahertyKRShollLMMyersJLKazerooniEAGrossBHOakSRCoelhoALEvanoffHDayEToewsGBJoshiADSchallerMAWatersBJaraiGWestwickJKunkelSLMartinezFJHogaboamCMTLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosisSci Transl Med2010257ra8210.1126/scitranslmed.3001510<?supplied-pmid 21068441?>21068441<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489788">http://f1000.com/prime/718489788</ext-link> </plain></SENT>
</text></ref><ref id="bib-074"><text><SENT sid="225" pm="."><plain>74CavassaniKAIshiiMWenHSchallerMALincolnPMLukacsNWHogaboamCMKunkelSLTLR3 is an endogenous sensor of tissue necrosis during acute inflammatory eventsJ Exp Med200820526092110.1084/jem.20081370<?supplied-pmid 18838547?>18838547<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1124517">http://f1000.com/prime/1124517</ext-link> </plain></SENT>
</text></ref><ref id="bib-075"><text><SENT sid="226" pm="."><plain>75KawaiTAkiraSThe role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNat Immunol2010113738410.1038/ni.1863<?supplied-pmid 20404851?>20404851 </plain></SENT>
</text></ref><ref id="bib-076"><text><SENT sid="227" pm="."><plain>76O'DwyerDNArmstrongMETrujilloGCookeGKeaneMPFallonPGSimpsonAJMillarABMcGrathEEWhyteMKHiraniNHogaboamCMDonnellySCThe Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosisAm J Respir Crit Care Med201318814425010.1164/rccm.201304-0760OC<?supplied-pmid 24070541?>24070541<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718121848">http://f1000.com/prime/718121848</ext-link> </plain></SENT>
</text></ref><ref id="bib-077"><text><SENT sid="228" pm="."><plain>77NothIKaminskiNIdiopathic pulmonary fibrosis: time to get personal?Am J Respir Crit Care Med20131881392410.1164/rccm.201311-1956ED<?supplied-pmid 24328772?>24328772 </plain></SENT>
</text></ref><ref id="bib-078"><text><SENT sid="229" pm="."><plain>78FinkJNOrtegaHGReynoldsHYCormierYFFanLLFranksTJKreissKKunkelSLynchDQuirceSRoseCSchleimerRPSchuylerMRSelmanMTroutDYoshizawaYNeeds and opportunities for research in hypersensitivity pneumonitisAm J Respir Crit Care Med2005171792810.1164/rccm.200409-1205WS<?supplied-pmid 15657460?>15657460 </plain></SENT>
</text></ref><ref id="bib-079"><text><SENT sid="230" pm="."><plain>79TakemuraTAkashiTKamiyaHIkushimaSAndoTOritsuMSawahataMOguraTPathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumoniaHistopathology20126110263510.1111/j.1365-2559.2012.04322.x<?supplied-pmid 22882269?>22882269 </plain></SENT>
</text></ref><ref id="bib-080"><text><SENT sid="231" pm="."><plain>80GilaniSRVugaLJLindellKOGibsonKFXueJKaminskiNValentineVGLindsayEKGeorgeMPSteeleCDuncanSRCD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosisPLoS ONE20105e895910.1371/journal.pone.0008959<?supplied-pmid 20126467?>20126467<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489789">http://f1000.com/prime/718489789</ext-link> </plain></SENT>
</text></ref><ref id="bib-081"><text><SENT sid="232" pm="."><plain>81Moro-GarcíaMAAlonso-AriasRLópez-LarreaCMolecular mechanisms involved in the aging of the T-cell immune responseCurr Genomics20121358960210.2174/138920212803759749<?supplied-pmid 23730199?>23730199 </plain></SENT>
</text></ref><ref id="bib-082"><text><SENT sid="233" pm="."><plain>82Herazo-MayaJDNothIDuncanSRKimSMaSTsengGCFeingoldEJuan-GuardelaBMRichardsTJLussierYHuangYVijRLindellKOXueJGibsonKFShapiroSDGarciaJoe GNKaminskiNPeripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosisSci Transl Med20135205ra136<?supplied-pmid 24089408?>24089408<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718131173">http://f1000.com/prime/718131173</ext-link> </plain></SENT>
</text></ref><ref id="bib-083"><text><SENT sid="234" pm="."><plain>83RosasIORenPAvilaNAChowCKFranksTJTravisWDMcCoyJPMayRMWuHNguyenDMArcos-BurgosMMacDonaldSDGochuicoBREarly interstitial lung disease in familial pulmonary fibrosisAm J Respir Crit Care Med200717669870510.1164/rccm.200702-254OC<?supplied-pmid 17641157?>17641157<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1090921">http://f1000.com/prime/1090921</ext-link> </plain></SENT>
</text></ref><ref id="bib-084"><text><SENT sid="235" pm="."><plain>84Marchal-SomméJUzunhanYMarchand-AdamSKambouchnerMValeyreDCrestaniBSolerPDendritic cells accumulate in human fibrotic interstitial lung diseaseAm J Respir Crit Care Med200717610071410.1164/rccm.200609-1347OC<?supplied-pmid 17717200?>17717200 </plain></SENT>
</text></ref><ref id="bib-085"><text><SENT sid="236" pm="."><plain>85DaniilZKitsantaPKapotsisGMathioudakiMKollintzaAKaratzaMMilic-EmiliJRoussosCPapirisSACD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosisRespir Res200568110.1186/1465-9921-6-81<?supplied-pmid 16042790?>16042790 </plain></SENT>
</text></ref><ref id="bib-086"><text><SENT sid="237" pm="."><plain>86Feghali-BostwickCATsaiCGValentineVGKantrowSStonerMWPilewskiJMGadgilAGeorgeMPGibsonKFChoiAugustine MKKaminskiNZhangYDuncanSRCellular and humoral autoreactivity in idiopathic pulmonary fibrosisJ Immunol20071792592910.4049/jimmunol.179.4.2592<?supplied-pmid 17675522?>17675522<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489790">http://f1000.com/prime/718489790</ext-link> </plain></SENT>
</text></ref><ref id="bib-087"><text><SENT sid="238" pm="."><plain>87ReilkoffRAPengHMurrayLAPengXRussellTMontgomeryRFeghali-BostwickCShawAHomerRJGulatiMMathurAEliasJAHerzogELSemaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosisAm J Respir Crit Care Med2013187180810.1164/rccm.201206-1109OC<?supplied-pmid 23220917?>23220917<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/717971657">http://f1000.com/prime/717971657</ext-link> </plain></SENT>
</text></ref><ref id="bib-088"><text><SENT sid="239" pm="."><plain>88KahloonRAXueJBhargavaACsizmadiaEOtterbeinLKassDJBonJSoejimaMLevesqueMCLindellKOGibsonKFKaminskiNBangaGOddisCVPilewskiJMSciurbaFCDonahoeMZhangYDuncanSRPatients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognosesAm J Respir Crit Care Med20131877687510.1164/rccm.201203-0506OC<?supplied-pmid 23262513?>23262513<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/717973243">http://f1000.com/prime/717973243</ext-link> </plain></SENT>
</text></ref><ref id="bib-089"><text><SENT sid="240" pm="."><plain>89Marchal-SomméJUzunhanYMarchand-AdamSValeyreDSoumelisVCrestaniBSolerPCutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosisJ Immunol20061765735910.4049/jimmunol.176.10.5735<?supplied-pmid 16670278?>16670278<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/14151">http://f1000.com/prime/14151</ext-link> </plain></SENT>
</text></ref><ref id="bib-090"><text><SENT sid="241" pm="."><plain>90XueJKassDJBonJVugaLTanJCsizmadiaEOtterbeinLSoejimaMLevesqueMCGibsonKFKaminskiNPilewskiJMDonahoeMSciurbaFCDuncanSRPlasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patientsJ Immunol201319120899510.4049/jimmunol.1203476<?supplied-pmid 23872052?>23872052<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718043484">http://f1000.com/prime/718043484</ext-link> </plain></SENT>
</text></ref><ref id="bib-091"><text><SENT sid="242" pm="."><plain>91CampbellDAPoulterLWJanossyGdu BoisRMImmunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivityThorax1985404051110.1136/thx.40.6.405<?supplied-pmid 3875162?>3875162 </plain></SENT>
</text></ref><ref id="bib-092"><text><SENT sid="243" pm="."><plain>92BrowningJLB cells move to centre stage: novel opportunities for autoimmune disease treatmentNat Rev Drug Discov200655647610.1038/nrd2085<?supplied-pmid 16816838?>16816838 </plain></SENT>
</text></ref><ref id="bib-093"><text><SENT sid="244" pm="."><plain>93VugaLJTedrowJRPanditKVTanJKassDJXueJChandraDLeaderJKGibsonKFKaminskiNSciurbaFCDuncanSRC-X-C Motif Chemokine 13 (CXCL13) Is a Prognostic Biomarker of Idiopathic Pulmonary FibrosisAm J Respir Crit Care Med20141899667410.1164/rccm.201309-1592OC<?supplied-pmid 24628285?>24628285<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718312185">http://f1000.com/prime/718312185</ext-link> </plain></SENT>
</text></ref><ref id="bib-094"><text><SENT sid="245" pm="."><plain>94AgrawalVSmartKJillingTHirschESurfactant protein (SP)-A suppresses preterm delivery and inflammation via TLR2PLoS ONE20138e6399010.1371/journal.pone.0063990<?supplied-pmid 23700442?>23700442 </plain></SENT>
</text></ref><ref id="bib-095"><text><SENT sid="246" pm="."><plain>95ChambersRCAbnormal wound healing responses in pulmonary fibrosis: focus on coagulation signallingEur Respir Rev200817130710.1183/09059180.00010905 </plain></SENT>
</text></ref><ref id="bib-096"><text><SENT sid="247" pm="."><plain>96ScottonCJKrupiczojcMAKönigshoffMMercerPFLeeYC GaryKaminskiNMorserJPostJMMaherTMNicholsonAGMoffattJDLaurentGJDerianCKEickelbergOChambersRCIncreased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injuryJ Clin Invest2009119255063<?supplied-pmid 19652365?>19652365<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/1165077">http://f1000.com/prime/1165077</ext-link> </plain></SENT>
</text></ref><ref id="bib-097"><text><SENT sid="248" pm="."><plain>97SteinhublSRPlatelets as mediators of inflammationHematol Oncol Clin North Am2007211152110.1016/j.hoc.2006.11.015<?supplied-pmid 17258122?>17258122 </plain></SENT>
</text></ref><ref id="bib-098"><text><SENT sid="249" pm="."><plain>98NavaratnamVFogartyAWMcKeeverTThompsonNJenkinsGJohnsonSRDolanGKumaranMPointonKHubbardRBPresence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control studyThorax2014692071510.1136/thoraxjnl-2013-203740<?supplied-pmid 24002055?>24002055<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718098688">http://f1000.com/prime/718098688</ext-link> </plain></SENT>
</text></ref><ref id="bib-099"><text><SENT sid="250" pm="."><plain>99NothIAnstromKJCalvertSBAndradeJ deFlahertyKRGlazerCKanerRJOlmanMAA placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2012186889510.1164/rccm.201202-0314OC<?supplied-pmid 22561965?>22561965<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/717951800">http://f1000.com/prime/717951800</ext-link> </plain></SENT>
</text></ref><ref id="bib-100"><text><SENT sid="251" pm="."><plain>100LeslieKOIdiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesisArch Pathol Lab Med201213659160010.5858/arpa.2011-0511-OA<?supplied-pmid 22136526?>22136526<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718489791">http://f1000.com/prime/718489791</ext-link> </plain></SENT>
</text></ref><ref id="bib-101"><text><SENT sid="252" pm="."><plain>101CoolCDGroshongSDRaiPRHensonPMStewartJSBrownKKFibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulumAm J Respir Crit Care Med2006174654810.1164/rccm.200602-205OC<?supplied-pmid 16799077?>16799077<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/30414">http://f1000.com/prime/30414</ext-link> </plain></SENT>
</text></ref><ref id="bib-102"><text><SENT sid="253" pm="."><plain>102GalvinJRFrazierAAFranksTJCollaborative radiologic and histopathologic assessment of fibrotic lung diseaseRadiology201025569270610.1148/radiol.10090717<?supplied-pmid 20501710?>20501710 </plain></SENT>
</text></ref><ref id="bib-103"><text><SENT sid="254" pm="."><plain>103DailDHPulmonary apical capAm J Surg Pathol200125134410.1097/00000478-200110000-00024<?supplied-pmid 11688475?>11688475 </plain></SENT>
</text></ref><ref id="bib-104"><text><SENT sid="255" pm="."><plain>104CarloniAPolettiVFermoLBellomoNChilosiMHeterogeneous distribution of mechanical stress in human lung: a mathematical approach to evaluate abnormal remodeling in IPFJ Theor Biol20133321364010.1016/j.jtbi.2013.04.038<?supplied-pmid 23665208?>23665208<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/718009926">http://f1000.com/prime/718009926</ext-link> </plain></SENT>
</text></ref><ref id="bib-105"><text><SENT sid="256" pm="."><plain>105WigginsJStricklandBTurner-WarwickMCombined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessmentRespir Med199084365910.1016/S0954-6111(08)80070-4<?supplied-pmid 2247666?>2247666 </plain></SENT>
</text></ref><ref id="bib-106"><text><SENT sid="257" pm="."><plain>106CottinVCordierJThe syndrome of combined pulmonary fibrosis and emphysemaChest20091361210.1378/chest.09-0538<?supplied-pmid 19584202?>19584202 </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list id="dl1"><def-item><term>BAL</term><def><p>bronchoalveolar lavage</p></def></def-item><def-item><term>COPD</term><def><p>chronic obstructive pulmonary disease</p></def></def-item><def-item><term>CCL</term><def><p>chemokine (C-C motif) ligand</p></def></def-item><def-item><term>CXCL</term><def><p>C-X-C motif chemokine</p></def></def-item><def-item><term>ER</term><def><p>endoplasmic reticulum</p></def></def-item><def-item><term>FIP</term><def><p>familial interstitial pneumonia</p></def></def-item><def-item><term>HP</term><def><p>hypersensitivity pneumonitis</p></def></def-item><def-item><term>HPS</term><def><p>Hermansky-Pudlak syndrome</p></def></def-item><def-item><term>ILD</term><def><p>interstitial lung disease</p></def></def-item><def-item><term>IPF</term><def><p>idiopathic pulmonary fibrosis</p></def></def-item><def-item><term>MMP</term><def><p>matrix metalloprotease</p></def></def-item><def-item><term>SNP</term><def><p>single-nucleotide polymorphism</p></def></def-item><def-item><term>TLR</term><def><p>Toll-like receptor</p></def></def-item><def-item><term>UIP</term><def><p>usual interstitial pneumonia</p></def></def-item></def-list></glossary></SecTag></back></article>
